Amgen stock has delivered an 88.5% total return over the past five years, and the latest Discounted Cash Flow (DCF) estimate currently points to the shares trading at a 43.0% discount to intrinsic value, while broader valuation checks paint a more mixed picture.

• Over five years, Amgen has returned 88.5%, which puts current investors in a strong position and raises the question of how much of the story is already reflected in the share price.
• Management confidence around a broad portfolio of growing therapies can support expectations for future cash flows, while any setback in key clinical programs or slower uptake for existing products may weigh on what investors are willing to pay for that growth.
• Amgen screens as a mixed case on value, with the stock passing about half of the checks and earning a 3 out of 6 valuation score, which suggests neither a clear bargain nor an obvious overvaluation.

The issue now is whether that apparent discount to intrinsic value can be justified once you line it up against Amgen's recent performance and the risks around its future cash flows.

Does Amgen Look Undervalued on Cash Flow?

The Discounted Cash Flow (DCF) approach here takes Amgen’s projected cash generation and brings it back to today’s dollars. Amgen produced about $9.1b in free cash flow over the latest twelve months, and the model assumes those cash flows grow over time rather than shrink. On that basis, the DCF points to an estimated intrinsic value of about $689 per share.

Compared with the current market price, that implies Amgen screens about 43% undervalued on this cash flow view. Because the company recently reported quarterly revenue of $8.62b with management expressing confidence in its long term growth drivers, investors may view the gap between price and model value as a reflection of ongoing caution around execution and pipeline risk rather than a lack of cash flow potential.

Pulling this together, the DCF workup suggests Amgen stock currently appears undervalued relative to the cash flows analysts expect it to produce.

Our Discounted Cash Flow (DCF) analysis suggests Amgen is undervalued by 43.0%. Track this in your watchlist or portfolio, or discover 49 more high quality undervalued stocks.

Where Does Amgen Sit on Earnings?

The P/E ratio is a useful yardstick for a mature, profitable company like Amgen because it ties the share price directly to current earnings. Right now, Amgen trades at about 27.2x earnings. That sits above the wider biotech industry average of roughly 16.9x, which reflects that many smaller biotechs have very different risk and earnings profiles.

A more tailored benchmark that looks at Amgen’s size, margins and risk profile points to a fair P/E of about 25.4x. Compared with that figure, the current 27.2x multiple is only modestly higher. It is also below the peer group average of around 48.0x, which is skewed by higher multiple stocks in the space.

Overall, Amgen’s current P/E suggests the stock is trading at roughly a fair level relative to what the company is earning today.

The Amgen Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Amgen sit on the Community page and connect directly to the valuation puzzle above by spelling out what future growth, margins and earnings would need to look like for the stock to be worth materially more or less than today's price. Each narrative ties a fair value estimate to a specific view of Amgen's potential catalysts and risks, which helps you track over time which storyline appears closer to how the company is actually progressing.

Amgen community views are split, with one camp seeing a broad cash generative pipeline and the other focused on legacy erosion and obesity competition risk.

Bull case: 9% undervalued

"The company's extensive global footprint, growing access initiatives, and direct-to-consumer strategies position its therapies for accelerated uptake among the rapidly expanding populations affected by aging and lifestyle-related chronic diseases…"

Bear case: 9% overvalued

"MariTide's commercial ramp-up will take years post-launch, while Amgen’s high-margin legacy moats (Prolia and Enbrel) are already eroding at a brutal 30%+ year-over-year clip right now…"

Do you think there's more to the story for Amgen? Head over to our Community to see what others are saying!

The Bottom Line

For Amgen, the Discounted Cash Flow (DCF) work points to a sizeable intrinsic value gap, while the current P/E suggests the stock is roughly in line with what the market is willing to pay for its earnings today. The mixed broader checks sit between those two views and keep the verdict finely balanced rather than clearly cheap or expensive. What matters most from here is whether Amgen can translate its pipeline and existing portfolio into the cash flows implied in the intrinsic value estimate without running into the clinical, competitive or uptake setbacks that the market is still pricing in.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.